Previous issues

D. Schijven, J.R. Zinkstok, J.J. Luykx

achtergrond Over genetische determinanten van psychiatrische aandoeningen wordt steeds meer bekend, maar het is voor veel psychiaters nog niet duidelijk hoe deze bevindingen zich vertalen naar de klinische praktijk. doel Ten eerste nieuw inzicht ...

Psychiatry and COVID-19

Beloop van covid-19-infecties en impact op mentale gezondheid; opzet van een landelijk casusregister

M.A. van Helvoort, V. van Dee, A. Dirks, D.S. Everaerd, M.J. Metz, M.A. van Schijndel, I. Tendolkar, J.R. Zinkstok, W. Cahn, A. Schellekens

Course of covid-19 infections and impact on mental health; setting up a national case register

Psychiatry and COVID-19

Melancholie bij ouderen in tijden van COVID-19

E. Roosens, J. De Fruyt, H. Van den Ameele, L. Lemey

Melancholy in the elderly in times of COVID-19

Commentary

Psychiatric stigma in the media and in education: continuous challenge

Psychological care, stigma of mental problems and the sense of competence of doctors; a survey among Flemish future doctors

K. Van den Broeck, B. van Gorp

background Stigmatisation by health care providers of people suffering from mental health problems adds to the treatment gap of mental illnesses and discrimination of people with a mental illness in somatic care. Future physicians’ effort may be ...

Original research

The development of anorexia nervosa in people with an autism spectrum disorder; a qualitative, retrospective study

V.C. Snouckaert, A.A. Spek

background To improve treatment options for women with autism spectrum disorder (ASD) in combination with anorexia nervosa (an), it is necessary to better understand which risk factors are involved in the development of an in this target audience...

Original research

The development of an mHealth app with young people in mental health care using Agile; a practical experiment

C.D. Verhagen, S.B.B. de Boer, S. Cardona cano, R.R.J.M. Vermeiren

background In recent years, many mobile health (mHealth) apps have been developed to support diagnostics and treatment, among other purposes. It is likely that involving patients closely in the development process will lead to more relevant apps....

Thesis article

From genetic findings to clinical practice in psychiatry: how genetics may enable Precision Psychiatry

D. Schijven, J.R. Zinkstok, J.J. Luykx

background Most psychiatric disorders are characterized by a complex genetic background where many common variants are involved. Nowadays, we are able to ‘read’ these variants, test for their association with phenotypes in genome-wide association...

Thesis article

Victimization among dual diagnosis patients and effectiveness of the sos training

M.M. de Waal, M.J. Kikkert, J.J.M. Dekker, A.E. Goudriaan

background Patients with a co-occurring substance use disorder and other mental disorder (dual diagnosis) are at increased risk of victimization: to become victims of for instance physical abuse, sexual abuse, and property crimes.
aim To exam...

Clinical practice

Carbamazepine and quetiapine: a neglected, but highly relevant interaction

S. van der Gaag, R.W. Kupka, P.M. Bet

We describe a case of concomitant use of carbamazepine and quetiapine, with a highly relevant interaction that requires attention. The combination of these drugs can be prescribed in psychiatry, for example in bipolar disorder, but also in other ...

Clinical practice

Alexander disease as an explanation for long-term unexplained psychiatric symptoms in a young girl

S.B.J. Oude ophuis, M.S. van der Knaap, P.F. Schothorst

Alexander disease is a rare genetic disorder, usually characterized by leukodystrophy, causing progressive degeneration of white matter in the central nervous system. We describe a case of a 7-year-old girl with long term medically unexplained sy...

Clinical practice

Autistic female with anxiety disorder and superior mesenteric artery syndrome

E. Lasat, K. Willems, S. Huysmans

An anxiety disorder can manifest in multiple ways. We saw a 21-year-old woman with an anxiety disorder in combination with superior mesenteric artery syndrome. For we know, this is the first description of this combination. There was also hypers...

Abstract

Olanzapine vermindert het risico op terugval na een psychotische depressie

E.C. Caubo, J.A. Godschalx-Dekker

Dutch-Flemish research

Genetica van bewegingsstoornissen: antipsychoticabehandeling op maat?

N. van der Burg

Psychiatry of the future

Antidepressieve placebo-effect voorspellen via corticale connectiviteit

Psychedelics and psychiatry

J.J. Breeksema, R.A. Schoevers, E. Vermetten, R. Van, M. Destoop, T. Birkenhäger, W. van den Brink

Scientific news

Psychedelica

Wekelijks verschijnen er talloze nieuwe publicaties in de wetenschappelijke psychiatrie-vakbladen. Voor de psychiater (i.o.) uit de dagelijkse praktijk maakt het Tijdschrift voor Psychiatrie in deze rubriek een selectie van recent verschenen publi...Read more

Essay

Effectivity of psychedelics in the treatment of psychiatric disorders; introduction

W. van den Brink, R.A. Schoevers, E. Vermetten, R. Van, J.J. Breeksema

Psychedelics in the treatment of depression, anxiety, and obsessive-compulsive disorder

J.J. Breeksema, W. van den Brink, J.K.E. Veraart, S.Y. Smith-apeldoorn, E. Vermetten, R.A. Schoevers

background There is a need for new, effective treatments for patients with (treatment-resistant) depressive disorders, anxiety disorders and obsessive-compulsive disorder (ocd). At the same time, there is renewed interest in psychedelics for the ...

Ketamine as an anesthetic, analgesic and antidepressant

S.Y. Smith-apeldoorn, J.K.E. Veraart, J. Kamphuis, J.J. Breeksema, W. van den Brink, M. Aan het rot, R.A. Schoevers

background Treatment-resistance occurs in about 30% of patients with depression. Therefore, there is an urgent need to identify new treatment strategies. Ketamine, originally developed as an anesthetic, is studied and applied as treatment for pat...

Psychedelics in the treatment of PTSD

E. Vermetten, E. Krediet, T. Bostoen, J.J. Breeksema, R.A. Schoevers, W. van den Brink

background Posttraumatic stress disorder (ptsd) is often a chronic condition, despite the availability of various evidence-based treatment options. Psychedelics offer new treatment opportunities.
aim An overview of the current evidence, thera...

Psychedelics in the treatment of substance use disorders and psychosis

W. van den Brink, J.J. Breeksema, E. Vermetten, R.A. Schoevers

background After psychedelics were banned in 1968, the flourishing research on the use of psychedelics in patients with a mental disorder stopped abruptly. Recently, we see a renaissance of this research.
aim To present an overview of what is...

Review

Psychedelics for existential distress in terminally ill patients

N. Schimmers, J.J. Breeksema, J.K.E. Veraart, W. van den Brink, R.A. Schoevers

background Existential distress in patients with a terminal illness is often associated with (symptoms of) anxiety and depression. Psychotherapeutic interventions seem effective but effects are short-lived. There are no proven effective pharmacol...

Microdosing with psychedelics: what do we know?